Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not ...

Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral ...

A study published in 2016 raised concerns that patients with liver cancer related to hepatitis C virus (HCV) may have a higher risk for recurrence if they are treated with direct-acting antiviral (DAA ...

According to data from eight studies being presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, there remains continued debate on whether patients are at risk of ...